CeloNova BioSciences
18615 Tuscany Stone
Suite 100
San Antonio
Texas
78258
United States
Tel: 210-489-4000
Fax: 210-403-2008
Website: http://www.celonova.com/
Email: info@celonova.com
35 articles about CeloNova BioSciences
-
CeloNova Announces New Strategic Direction Focused on Creating Partnership
4/7/2022
CeloNova BioSciences, Inc. (CeloNova), developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, today announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body.
-
COBRA PzF NanoCoated Coronary Stent Demonstrates Exceptional Long-Term Safety and Low ID-TLR at Five Years in Highly Complex Patients Undergoing PCI
5/13/2021
CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced its flagship COBRA PzF NanoCoated Coronary Stent (NCS) achieved exceptional long-term ischemic safety of 0% definite and probable stent thrombosis (ST) and low ischemia-driven target lesion revascularization
-
CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI
10/17/2020
The novel non-DES, non-BMS COBRA PzF NanoCoated Coronary Stent (NCS) with just 14-days DAPT demonstrated statistically less bleeding (BARC 1-5) compared to the DES arm at 3 or 6 months DAPT post-PCI, low 0.6% ST and low 3.7% ischemic-driven TLR at 6 months.
-
CeloNova Announces Enrollment Completion of World's First Randomized Control, 14-Day DAPT Trial
6/1/2020
CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today annou
-
CeloNova Announces Appointment of New President and CEO
8/6/2019
Company positions itself for expected near-term commercial growth within coronary stent market treating high bleeding risk patients undergoing PCI
-
CeloNova Signs Agreement with HealthTrust for Game-Changing New Coronary Stent
2/8/2019
COBRA PzF NanoCoated Coronary Stent (NCS) is an ideal treatment solution for high-risk patients unable to tolerate long-term DAPT
-
CeloNova's COBRA PzF NanoCoated Coronary Stent Being Studied with 14-day DAPT in High Bleeding Risk Patients
10/26/2017
CeloNova BioSciences today announced that the FDA approved expansion of CeloNova's ongoing clinical trial of its proprietary COBRA PzF NCS with 14-day DAPT in complex patients, such as those who are at high bleeding risk.
-
CeloNova BioSciences Release: FDA Approves NanoCoated Coronary Stent System Using DSG, Inc.’s eClinical Systems
3/23/2017
-
CeloNova BioSciences Release: Medtech Announces Clinical Results From Pivotal Pzf SHIELD Clinical Trial Published In The Journal Of The American College Of Cardiology: Cardiovascular Interventions
1/24/2017
-
After Scoring a $70 Million Deal With Boston Scientific, CeloNova BioSciences CEO Heads to Nonprofit
9/20/2016
-
Boston Scientific Buys CeloNova BioSciences' Interventional Radiology Biz for $70 Million+
11/10/2015
-
CeloNova BioSciences Announces FDA Approval To Start A Randomized Trial For The COBRA PzF Coronary Stent System
9/21/2015
-
CeloNova BioSciences Announces Accelerated IDE Trial Enrollment Completion For Its COBRA Pzf Coronary Stent System
2/19/2015
-
CeloNova BioSciences Receives Expanded Indication For Benign Prostatic Hyperplasia (BPH)
1/14/2015
-
GRCI 2014 Update: CeloNova BioSciences' COBRA Pzf™ Coronary Stent Achieves A Low 3% TLR With Short DAPT
12/12/2014
-
CeloNova BioSciences's Super-Selective Embolic Microsphere With Drug Loading Capabilities Could Mean Improved Quality Of Life And Overall Survival For Liver Cancer Patients
10/30/2014
-
CeloNova BioSciences Release: First-In-Man Study Of The COBRA PzF Coronary Stent Shows Promising Results Highlighted By Short, 30-Day Dual-Antiplatelet Therapy And Low, 3% TLR Rate
9/16/2014
-
CeloNova BioSciences Receives Expanded Indication in Liver Cancer
9/3/2014
-
CeloNova BioSciences’s Coronary Stent System Could Mean Faster Healing Of Arteries And Greatly Reduced Use Of Blood-Thinning Medication
3/18/2014
-
CeloNova BioSciences Release: New Treatment Option For Women An Alternative To Hysterectomy
3/11/2014